Can-Fite BioPharma Ltd.
Piclidenoson
psoriasis
Date
TBD
Phase 3 readout · Date TBD estimated
What's at stake
Phase 3 trial results for Piclidenoson in psoriasis are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 12h ago
“The drug’s mechanism of action entails inhibition of the inflammatory cytokines interleukin 17 and 23 (IL-17 and IL-23) and the induction of apoptosis of patients’ skin cell keratinocytes involved with the disease pathogenicity.”